NCT00379587View on ClinicalTrials.gov

Rituximab for Prevention of Chronic GVHD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Hematological Malignancies
Interventions
DRUG

Rituximab

Rituximab at months 3, 6, 9 and 12 post-transplant

DRUG

375 mg/m2 RRituximab

Rituximab 375 mg/m2 q3months

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (2)

Genentech, Inc.
Biogen
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Biogen

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER